Trial Summary
What is the purpose of this trial?This trial is testing whether fluvoxamine can help people with long-term COVID-19 symptoms, especially those affecting brain function. The study involves adults who had COVID-19 a while ago and are still experiencing issues like 'brain fog.' The medication works by balancing brain chemicals and supporting the immune system to reduce symptoms. Fluvoxamine has shown potential in reducing inflammation in COVID-19 patients.
Eligibility Criteria
This trial is for Missouri or Illinois residents aged 25+ who've had COVID-19 symptoms or a positive test at least 3 months ago and are experiencing cognitive issues for the past 2 months. Excluded are those with bipolar disorder on certain meds, severe illnesses, hospitalization at study start, immunocompromised status, taking specific drugs like SSRIs/SNRIs, or enrolled in another COVID-19 medication trial.Inclusion Criteria
Able to provide informed consent
Currently reside in Missouri or Illinois
I am 25 years old or older.
+3 more
Exclusion Criteria
I am currently taking medication for depression or anxiety.
I am unable to understand and give consent for treatment.
I am immunocompromised due to a transplant, high dose steroids, or specific medication.
+9 more
Participant Groups
The trial is examining if fluvoxamine can alleviate long-term symptoms of COVID-19. Fluvoxamine is an SSRI approved for OCD that has shown promise in reducing hospitalizations in acute COVID cases. Participants will be assessed to see if their post-COVID condition improves with this treatment.
2Treatment groups
Experimental Treatment
Placebo Group
Group I: FluvoxamineExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Washington University School of MedicineSaint Louis, MO
Loading ...
Who Is Running the Clinical Trial?
Washington University School of MedicineLead Sponsor
Balvi COVID FundCollaborator
BJH Townley FundCollaborator